{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "c530716a",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## üìã Agents Information\n",
    "\n",
    "---\n",
    "\n",
    "### Simple Prescription Agent\n",
    "- **Type**: Simple Agent\n",
    "- **Name**: `simple_prescription_agent`\n",
    "- **Subagents**: None\n",
    "- **Returned State**: `results_criticality`\n",
    "- **Dashboard Metrics**: Overall prescription safety level (low/medium/high)\n",
    "\n",
    "Schema Output Example:\n",
    "```json\n",
    "{\n",
    "  \"overall_criticality\": \"medium\",\n",
    "  \"description\": \"Overall safety assessment of the prescription.\"\n",
    "}\n",
    "```\n",
    "\n",
    "### Parallel Analysis Agent\n",
    "- **Type**: Parallel Agent\n",
    "- **Name**: `parallel_analyzer_agent`\n",
    "- **Subagents**: `drug_analysis_agent`, `dose_drug_analysis_agent`, `route_drug_analysis_agent`\n",
    "- **Returned State**: `synthesized_results_criticality`\n",
    "- **Dashboard Metrics**: Individual criticality levels for drug, dose, and route analysis\n",
    "\n",
    "Schema Output Example:\n",
    "```json\n",
    "{\n",
    "  \"level_drug\": \"medium\",\n",
    "  \"level_dose\": \"high\", \n",
    "  \"level_route\": \"low\",\n",
    "  \"description\": \"Synthesis of drug, dose, and route analysis criticality levels.\"\n",
    "}\n",
    "```\n",
    "\n",
    "### Sequential Health Analyzer Agent\n",
    "- **Type**: Sequential Agent\n",
    "- **Name**: `sequential_analyzer_agent`\n",
    "- **Subagents**: `general_health_agent`, `treatment_assessment_agent`, `synthesizer_health_report_agent`\n",
    "- **Returned State**: `synthesized_health_report`\n",
    "- **Dashboard Metrics**: \n",
    "  - Treatment Duration Criticality (low/medium/high)\n",
    "  - Patient Compliance Risk (low/medium/high) \n",
    "  - Lifestyle Impact Level (low/medium/high)\n",
    "  - Monitoring Frequency Criticality (low/medium/high)\n",
    "  - Executive Summary (text)\n",
    "  - Actionable Recommendations (text)\n",
    "\n",
    "Schema Output Example:\n",
    "```json\n",
    "{\n",
    "  \"treatment_duration_criticality\": \"medium\",\n",
    "  \"patient_compliance_criticality\": \"high\",\n",
    "  \"lifestyle_impact_criticality\": \"low\", \n",
    "  \"monitoring_frequency_criticality\": \"medium\",\n",
    "  \"executive_summary\": \"Patient profile and treatment overview...\",\n",
    "  \"actionable_recommendations\": \"Specific healthcare provider actions...\"\n",
    "}\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "## üìä Dashboard Integration\n",
    "\n",
    "**Agent Outputs ‚Üí Dashboard Features:**\n",
    "\n",
    "1. **Safety Alerts Panel**: Simple + Parallel agent criticality levels\n",
    "2. **Treatment Timeline Widget**: Sequential agent duration assessment  \n",
    "3. **Patient Risk Matrix**: Compliance + lifestyle impact scores\n",
    "4. **Monitoring Schedule**: Frequency criticality + recommendations\n",
    "5. **Executive Summary Card**: Consolidated patient overview\n",
    "6. **Action Items List**: Prioritized healthcare provider tasks\n",
    "\n",
    "**Main Function:** `run_agent(agent_name, input_data, user_id)`\n",
    "\n",
    "**Workflow:** Create Session ‚Üí Execute Agent ‚Üí Get State ‚Üí Delete Session\n",
    "\n",
    "**API:** `http://localhost:8000` (ADK server running)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "a438a42e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['parallel_analyzer_agent',\n",
       " 'search_agent',\n",
       " 'sequential_analyzer_agent',\n",
       " 'simple_prescription_agent']"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "r = requests.get(f\"{BASE_URL}/list-apps\", timeout=30)\n",
    "r.raise_for_status()\n",
    "apps = r.json()\n",
    "apps"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "92a3ecda",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['parallel_analyzer_agent',\n",
       " 'search_agent',\n",
       " 'sequential_analyzer_agent',\n",
       " 'simple_prescription_agent']"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "import uuid\n",
    "\n",
    "# Configura√ß√£o\n",
    "BASE_URL = \"http://localhost:8000\"\n",
    "BASE_URL = \"https://adk-server-health-894271896157.europe-west1.run.app\"\n",
    "\n",
    "# Nomes dos agentes dispon√≠veis\n",
    "AGENTS = {\n",
    "    \"lead\": \"lead_qualification_agent\",\n",
    "    \"search\": \"search_agent\", \n",
    "    \"essay\": \"essay_analyzer_agent\",\n",
    "    \"prescription\": \"simple_prescription_agent\"\n",
    "}\n",
    "\n",
    "def get_all_apps():\n",
    "    \"\"\"\n",
    "    Recupera a lista de todos os aplicativos dispon√≠veis na API ADK.\n",
    "    \n",
    "    Returns:\n",
    "        list - Lista de aplicativos.\n",
    "    \"\"\"\n",
    "    response = requests.get(f\"{BASE_URL}/list-apps\")\n",
    "    return response.json()\n",
    "\n",
    "all_apps = get_all_apps()\n",
    "all_apps"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "65e6ad85",
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_agent(agent_name: str, input_data: str, user_id: str = \"u_test\") -> dict:\n",
    "    \"\"\"\n",
    "    Executa um agente e retorna o estado completo.\n",
    "    Cria e deleta a sess√£o automaticamente.\n",
    "    \"\"\"\n",
    "    session_id = f\"s_{uuid.uuid4().hex[:8]}\"\n",
    "    \n",
    "    # 1. Criar sess√£o\n",
    "    requests.post(\n",
    "        f\"{BASE_URL}/apps/{agent_name}/users/{user_id}/sessions/{session_id}\",\n",
    "        json={\"state\": {}, \"user_id\": user_id, \"session_id\": session_id}\n",
    "    )\n",
    "    \n",
    "    # 2. Executar agente\n",
    "    requests.post(\n",
    "        f\"{BASE_URL}/run\",\n",
    "        json={\n",
    "            \"appName\": agent_name,\n",
    "            \"userId\": user_id,\n",
    "            \"sessionId\": session_id,\n",
    "            \"newMessage\": {\"parts\": [{\"text\": input_data}], \"role\": \"user\"}\n",
    "        }\n",
    "    )\n",
    "    \n",
    "    # 3. Obter resultado\n",
    "    response = requests.get(\n",
    "        f\"{BASE_URL}/apps/{agent_name}/users/{user_id}/sessions/{session_id}\"\n",
    "    )\n",
    "    \n",
    "    # 4. Deletar sess√£o\n",
    "    requests.delete(\n",
    "        f\"{BASE_URL}/apps/{agent_name}/users/{user_id}/sessions/{session_id}\"\n",
    "    )\n",
    "    \n",
    "    return response.json().get(\"state\", {})\n",
    "\n",
    "\n",
    "def get_all_sessions(agent_name: str, user_id: str = \"u_test\") -> list:\n",
    "    \"\"\"Obt√©m todas as sess√µes de um usu√°rio para um agente espec√≠fico.\"\"\"\n",
    "    response = requests.get(\n",
    "        f\"{BASE_URL}/apps/{agent_name}/users/{user_id}/sessions\"\n",
    "    )\n",
    "    return response.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "956da2a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "# load data\n",
    "with open(\"../data/inputs_to_agent_fake_mimic3.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    fake_admissions = json.load(f)\n",
    "    \n",
    "regular = fake_admissions[0]\n",
    "poisoned = fake_admissions[9]\n",
    "\n",
    "regular_example = f\"\"\"\n",
    "data: {regular[\"admission_str\"]}\n",
    "\n",
    "current_prescription: {regular[\"current_prescription\"]}\n",
    "\"\"\"\n",
    "\n",
    "poisoned_example = f\"\"\"\n",
    "data: {poisoned[\"admission_str\"]}\n",
    "current_prescription: {poisoned[\"current_prescription\"]}\n",
    "\"\"\"\n",
    "\n",
    "very_poisoned_example = f\"\"\"\n",
    "\n",
    "data: Subject ID: 9\n",
    "Admission ID: 199395\n",
    "Admission Date: 6959286900000\n",
    "Discharge Date: 6960348000000\n",
    "Insurance: Medicare\n",
    "Age: None\n",
    "Gender: F\n",
    "Language: None\n",
    "Marital Status: MARRIED\n",
    "Ethnicity: WHITE\n",
    "Creatinine: 2.3 mg/dL\n",
    "Hemoglobin: 11.0 g/dL\n",
    "Potassium: 4.6 mEq/L\n",
    "Sodium: 143.0 mEq/L\n",
    "Notes (24h Summary): None\n",
    "Prescriptions:   - Drug: Oxycodone-Acetaminophen, Type: MAIN, Dose: 1-2 TAB, Form: None, Route: PO, Start: 2190-07-16 00:00:00, Stop: 2190-07-18 00:00:00--------------------------------\n",
    "  - Drug: Oxycodone-Acetaminophen, Type: MAIN, Dose: 5-10 ml, Form: None, Route: PO, Start: 2190-07-16 00:00:00, Stop: 2190-07-18 00:00:00--------------------------------\n",
    "  - Drug: Amiodarone HCl, Type: MAIN, Dose: 150 mg, Form: None, Route: IV, Start: 2190-07-17 00:00:00, Stop: 2190-07-18 00:00:00--------------------------------\n",
    "  - Drug: GlipiZIDE, Type: MAIN, Dose: 7.5 mg, Form: None, Route: PO, Start: 2190-07-17 00:00:00, Stop: 2190-07-21 00:00:00--------------------------------\n",
    "  - Drug: Amiodarone HCl, Type: MAIN, Dose: 400 mg, Form: None, Route: PO, Start: 2190-07-18 00:00:00, Stop: 2190-07-21 00:00:00--------------------------------\n",
    "  - Drug: Potassium Chloride, Type: MAIN, Dose: 20 mEq, Form: None, Route: PO, Start: 2190-07-18 00:00:00, Stop: 2190-07-19 00:00:00--------------------------------\n",
    "  - Drug: Oxycodone-Acetaminophen, Type: MAIN, Dose: 1-2 TAB, Form: None, Route: PO, Start: 2190-07-19 00:00:00, Stop: 2190-07-21 00:00:00--------------------------------\n",
    "  - Drug: Amiodarone HCl, Type: MAIN, Dose: 150 mg, Form: None, Route: IV, Start: 2190-07-19 00:00:00, Stop: 2190-07-20 00:00:00--------------------------------\n",
    "  - Drug: Magnesium Sulfate, Type: MAIN, Dose: 2 gm, Form: None, Route: IV, Start: 2190-07-19 00:00:00, Stop: 2190-07-20 00:00:00--------------------------------\n",
    "  - Drug: Metoprolol, Type: MAIN, Dose: 12.5 mg, Form: None, Route: PO, Start: 2190-07-20 00:00:00, Stop: 2190-07-21 00:00:00--------------------------------\n",
    "----------------------------------------\n",
    "\n",
    "current_prescription: 'drug': 'Fentanyl Patch', 'drug_type': 'MAIN', 'dose_val': '22500', 'dose_unit': 'PUFF', 'form': None, 'route': 'DWELL', 'starttime': '2190-07-20 00:00:00', 'stoptime': '2190-07-25 00:00:00'\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "b5559985",
   "metadata": {},
   "outputs": [],
   "source": [
    "state_regular = run_agent(\"parallel_analyzer_agent\", \n",
    "                  regular_example)\n",
    "\n",
    "state_poisoned = run_agent(\"parallel_analyzer_agent\", \n",
    "                  poisoned_example)\n",
    "\n",
    "state_very_poisoned = run_agent(\"parallel_analyzer_agent\", \n",
    "                  very_poisoned_example)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "5a0c9fed",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'state': {},\n",
       " 'user_id': 'u_test',\n",
       " 'session_id': 's_f554391f',\n",
       " 'drug_analysis': 'MethylPREDNISolone Sodium Succinate does not have any critical safety alerts that warrant immediate intervention. Therefore, the safety profile is considered LOW.',\n",
       " 'route_drug_analysis': 'The prescription specifies subcutaneous administration of MethylPREDNISolone Sodium Succinate. While IV administration is common, SC administration is less typical and might affect absorption rates, but does not present a high risk of immediate toxicity. GRADE: MEDIUM\\n',\n",
       " 'dose_drug_analysis': 'The prescribed dose of MethylPREDNISolone Sodium Succ (1500-2900 mg SC) is significantly above typical doses and may represent a critical overdose risk, especially given the subcutaneous route. GRADE: HIGH\\n',\n",
       " 'synthesized_results_criticality': {'level_drug': 'LOW',\n",
       "  'level_dose': 'HIGH',\n",
       "  'level_route': 'MEDIUM',\n",
       "  'description': 'The synthesized safety assessment indicates a HIGH concern due to the significantly elevated dose of MethylPREDNISolone Sodium Succinate (1500-2900 mg SC). Although the drug itself has a low-risk profile, and the subcutaneous route presents a medium risk, the substantial overdose potential necessitates immediate attention. The physician needs to confirm the dose and route are appropriate.'}}"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state_regular"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "05330720",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "data: Subject ID: 0\n",
      "Admission ID: 169938\n",
      "Admission Date: 4323585540000\n",
      "Discharge Date: 4324203900000\n",
      "Insurance: Medicare\n",
      "Age: None\n",
      "Gender: M\n",
      "Language: None\n",
      "Marital Status: UNKNOWN (DEFAULT)\n",
      "Ethnicity: WHITE\n",
      "Creatinine: 1.1 mg/dL\n",
      "Hemoglobin: 10.0 g/dL\n",
      "Potassium: 3.7 mEq/L\n",
      "Sodium: 142.0 mEq/L\n",
      "Notes (24h Summary): None\n",
      "Prescriptions:   - Drug: SW, Type: BASE, Dose: 100 ml, Form: None, Route: IV, Start: 2107-01-06 00:00:00, Stop: 2107-01-07 00:00:00--------------------------------\n",
      "  - Drug: NS, Type: BASE, Dose: 500 ml, Form: None, Route: IV, Start: 2107-01-06 00:00:00, Stop: 2107-01-07 00:00:00--------------------------------\n",
      "  - Drug: NS, Type: BASE, Dose: 500 ml, Form: None, Route: IV, Start: 2107-01-06 00:00:00, Stop: 2107-01-07 00:00:00--------------------------------\n",
      "  - Drug: Iso-Osmotic Dextrose, Type: BASE, Dose: 200 ml, Form: None, Route: IV, Start: 2107-01-07 00:00:00, Stop: 2107-01-08 00:00:00--------------------------------\n",
      "  - Drug: Fat Emulsion 20%, Type: BASE, Dose: 250 ml, Form: None, Route: IV, Start: 2107-01-07 00:00:00, Stop: 2107-01-11 00:00:00--------------------------------\n",
      "  - Drug: SW, Type: BASE, Dose: 100 ml, Form: None, Route: IV, Start: 2107-01-08 00:00:00, Stop: 2107-01-08 00:00:00--------------------------------\n",
      "  - Drug: Amino Acids 4.25% W/ Dextrose 5%, Type: BASE, Dose: 1000 ml, Form: None, Route: IV, Start: 2107-01-08 00:00:00, Stop: 2107-01-08 00:00:00--------------------------------\n",
      "  - Drug: Amino Acids 4.25% W/ Dextrose 5%, Type: BASE, Dose: 1000 ml, Form: None, Route: IV, Start: 2107-01-08 00:00:00, Stop: 2107-01-09 00:00:00--------------------------------\n",
      "  - Drug: NS, Type: BASE, Dose: 100 ml, Form: None, Route: IV, Start: 2107-01-09 00:00:00, Stop: 2107-01-10 00:00:00--------------------------------\n",
      "  - Drug: D5W, Type: BASE, Dose: 50 ml, Form: None, Route: IV, Start: 2107-01-09 00:00:00, Stop: 2107-01-09 00:00:00--------------------------------\n",
      "----------------------------------------\n",
      "\n",
      "\n",
      "current_prescription: {'drug': 'MethylPREDNISolone Sodium Succ', 'drug_type': 'BASE', 'dose_val': '1500-2900', 'dose_unit': 'mg', 'form': None, 'route': 'SC', 'starttime': '2107-01-10 00:00:00', 'stoptime': '2107-01-11 00:00:00'}\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(regular_example)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "15c804ea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'state': {},\n",
       " 'user_id': 'u_test',\n",
       " 'session_id': 's_a268b691',\n",
       " 'general_health_report': \"Here's a structured health report based on the provided patient data:\\n\\n**1. Patient Profile Summary**\\n\\n*   **Subject ID:** 0\\n*   **Admission ID:** 169938\\n*   **Gender:** Male (M)\\n*   **Age:** Not specified\\n*   **Ethnicity:** White\\n*   **Marital Status:** Unknown\\n*   **Insurance:** Medicare\\n*   **Admission Date:** 4323585540000 (Timestamp format)\\n*   **Discharge Date:** 4324203900000 (Timestamp format)\\n\\n**2. Identified Health Conditions**\\n\\n*   Anemia (Hemoglobin: 10.0 g/dL, which is below the normal range).\\n*   Creatinine: 1.1 mg/dL - Within normal limits, suggesting adequate kidney function for the moment.\\n*   Potassium: 3.7 mEq/L and Sodium: 142.0 mEq/L - Both within normal limits.\\n\\n**3. Analysis of Prescriptions in Relation to Clinical Picture**\\n\\n*   **Baseline IV Fluids (SW, NS, Iso-Osmotic Dextrose, D5W):** The patient received various intravenous fluids (Sterile Water, Normal Saline, Dextrose solutions). These likely address hydration and electrolyte balance.\\n*   **Fat Emulsion 20%:** This provides a source of calories and essential fatty acids, often used in patients who cannot receive adequate nutrition through oral intake.\\n*   **Amino Acids 4.25% W/ Dextrose 5%:** This is a form of parenteral nutrition, providing essential amino acids and glucose. It's likely used to support nutritional needs, possibly due to an inability to eat or increased metabolic demands.\\n*   **MethylPREDNISolone Sodium Succ (Current Prescription):** A corticosteroid with anti-inflammatory and immunosuppressant properties. Given the high dose (1500-2900 mg SC), it's likely being used to treat a severe inflammatory or immune-mediated condition. The specific indication cannot be determined without more clinical context.\\n\\n**4. General Observations About Treatment Adequacy**\\n\\n*   The administration of IV fluids and parenteral nutrition suggests the patient may have had difficulty with oral intake or had increased nutritional needs.\\n*   The use of MethylPREDNISolone at a high dose indicates a serious underlying condition requiring aggressive anti-inflammatory/immunosuppressive treatment.\\n\\n**5. Points That Deserve Attention**\\n\\n*   **Reason for Anemia:** The cause of the patient's anemia (Hemoglobin 10.0 g/dL) should be investigated (e.g., blood loss, iron deficiency, chronic disease).\\n*   **Justification for High-Dose MethylPREDNISolone:** The medical records should clearly document the specific indication and rationale for using such a high dose of MethylPREDNISolone, given its potential side effects.\\n*   **Nutritional Status Monitoring:** Given the use of parenteral nutrition, the patient's nutritional status (electrolytes, glucose, fluid balance) should be closely monitored.\\n*   **Age:** The patient's age is missing, which is crucial for a comprehensive assessment.\\n\",\n",
       " 'treatment_impact_assessment': \"Okay, I will assess the treatment duration and potential patient impacts based on the provided patient data and the general health report.\\n\\n**TREATMENT DURATION ANALYSIS:**\\n\\n*   **Estimated treatment duration:**\\n    *   MethylPREDNISolone Sodium Succ: Currently prescribed for a short duration (2107-01-10 to 2107-01-11). However, given the high dose, this is likely the initial phase of a longer treatment plan that will involve tapering the dose. Without further information, it's difficult to estimate the total duration. It could range from a few weeks to several months, depending on the underlying condition and response to treatment.\\n    *   IV fluids and parenteral nutrition: These were administered for a few days, likely to address acute needs. The duration depends on when the patient can resume adequate oral intake.\\n*   **Short-term vs. long-term therapy:**\\n    *   MethylPREDNISolone: Given the high initial dose, the patient will likely require long-term therapy.\\n    *   IV fluids and parenteral nutrition: likely short-term\\n*   **Factors that may extend or shorten the treatment period:**\\n    *   Response to MethylPREDNISolone: A good response may allow for a quicker taper. Poor response may necessitate a longer or higher-dose treatment.\\n    *   Underlying condition: The nature and severity of the underlying condition requiring MethylPREDNISolone will significantly impact the duration.\\n    *   Development of side effects: Significant side effects from MethylPREDNISolone may necessitate a slower taper or alternative treatment.\\n    *   Nutritional status: If the patient's nutritional status does not improve, parenteral nutrition might be needed for a longer duration.\\n*   **Monitoring frequency requirements:**\\n    *   MethylPREDNISolone: Frequent monitoring of blood pressure, glucose, electrolytes, and signs of infection is essential, especially during high-dose therapy. Monitoring for psychiatric side effects is also important.\\n    *   Nutritional status: Daily monitoring of electrolytes, fluid balance, and glucose is critical.\\n    *   Anemia: Regular monitoring of hemoglobin levels is needed to assess if further intervention is needed.\\n\\n**PATIENT IMPACT ASSESSMENT:**\\n\\n*   **Correlation with patient's medical history:**\\n    *   The anemia (hemoglobin 10.0 g/dL) could be exacerbated by MethylPREDNISolone.\\n    *   The patient's overall condition may be impacted by the high dose of MethylPREDNISolone if he has any underlying cardiovascular or renal issues.\\n*   **Potential side effects based on patient profile:**\\n    *   Since the patient is on Medicare, it's possible they are elderly, which increases the risk of MethylPREDNISolone-related side effects such as:\\n        *   Increased risk of infection\\n        *   Hyperglycemia (especially if there is a history of diabetes)\\n        *   Fluid retention and hypertension\\n        *   Osteoporosis (with long-term use)\\n        *   Muscle weakness\\n    *   Electrolyte imbalances from MethylPREDNISolone\\n*   **Quality of life considerations during treatment:**\\n    *   High-dose MethylPREDNISolone can significantly impact quality of life due to side effects (mood changes, weight gain, insomnia, etc.).\\n    *   Parenteral nutrition can restrict mobility and daily activities.\\n*   **Impact on existing conditions or comorbidities:**\\n    *   MethylPREDNISolone can worsen diabetes, hypertension, and heart failure.\\n*   **Functional limitations or lifestyle adjustments needed:**\\n    *   The patient may need to limit sodium intake due to potential fluid retention from MethylPREDNISolone.\\n    *   Depending on the underlying condition, the patient may have significant functional limitations.\\n    *   Increased risk of infection requires caution in social interactions.\\n\\n**HISTORICAL CORRELATION:**\\n\\n*   **How current treatment aligns with past medical history:**\\n    *   Without knowing the patient's age and past medical history, it's challenging to determine specific risk factors.\\n*   **Previous treatment responses or complications:**\\n    *   Unknown without more information.\\n*   **Risk factors specific to this patient:**\\n    *   White ethnicity does not contribute significant risk factors.\\n*   **Contraindications based on medical background:**\\n    *   Need to rule out active infections before starting high-dose MethylPREDNISolone.\\n\\n**IMPACT ANNOTATIONS:**\\n\\n*   **Physical impacts:**\\n    *   Fatigue and muscle weakness from MethylPREDNISolone.\\n    *   Fluid retention and weight gain.\\n    *   Increased risk of infection.\\n    *   Potential for hyperglycemia.\\n*   **Emotional/psychological impacts:**\\n    *   Mood swings, anxiety, and depression from MethylPREDNISolone.\\n    *   Insomnia.\\n*   **Social/family life implications:**\\n    *   The patient may need assistance with daily activities due to fatigue or muscle weakness.\\n    *   Increased risk of infection may limit social interactions.\\n*   **Work/professional activity considerations:**\\n    *   The patient's ability to work will likely be impaired during high-dose MethylPREDNISolone therapy.\\n*   **Financial implications of extended treatment:**\\n    *   MethylPREDNISolone and parenteral nutrition can be expensive, even with Medicare.\\n    *   The patient may require home health care or other support services, which can add to the financial burden.\\n\\n**Specific Notes:**\\n\\n*   The high dose of MethylPREDNISolone is a significant concern. It's crucial to understand the underlying reason for this treatment and to monitor the patient closely for side effects.\\n*   The anemia should be investigated and treated appropriately.\\n*   Nutritional support is essential, but efforts should be made to transition the patient back to oral intake as soon as possible.\\n*   The missing age is a critical piece of information for a comprehensive assessment.\\n\",\n",
       " 'synthesized_health_report': {'treatment_duration_criticality': 'medium',\n",
       "  'patient_compliance_criticality': 'medium',\n",
       "  'lifestyle_impact_criticality': 'high',\n",
       "  'monitoring_frequency_criticality': 'high',\n",
       "  'executive_summary': 'Male patient with anemia is receiving high-dose MethylPREDNISolone for an unknown condition, along with parenteral nutrition. Treatment duration is uncertain, but likely to be extended. Key risks include medication side effects, nutritional imbalances and potential for infection. Close monitoring and patient education are crucial.',\n",
       "  'actionable_recommendations': '- Investigate the cause of anemia and treat appropriately.\\n- Clearly document the indication for high-dose MethylPREDNISolone.\\n- Monitor blood glucose, electrolytes, blood pressure, and mental status closely due to MethylPREDNISolone.\\n- Implement infection control measures.\\n- Consult a dietitian to optimize nutritional support and transition to oral intake as soon as feasible.\\n- Educate the patient about potential side effects and the importance of adherence to the treatment plan.\\n- Schedule regular follow-up appointments to assess treatment response and adjust the medication regimen.'}}"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state_regular_sequential"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "6d0ff464",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'state': {},\n",
       " 'user_id': 'u_test',\n",
       " 'session_id': 's_1f23abda',\n",
       " 'general_health_report': \"## Patient Health Analysis Report\\n\\n**1. Patient Profile Summary:**\\n\\n*   **Subject ID:** 9\\n*   **Admission ID:** 199395\\n*   **Admission Date:** 6959286900000\\n*   **Discharge Date:** 6960348000000\\n*   **Age:** Not available\\n*   **Gender:** Female\\n*   **Marital Status:** Married\\n*   **Ethnicity:** White\\n*   **Insurance:** Medicare\\n*   **Creatinine:** 2.3 mg/dL (Elevated)\\n*   **Hemoglobin:** 11.0 g/dL (Low)\\n*   **Potassium:** 4.6 mEq/L (Normal)\\n*   **Sodium:** 143.0 mEq/L (Normal)\\n\\n**2. Identified Health Conditions:**\\n\\nBased on the available data, the following potential health conditions can be inferred:\\n\\n*   **Renal Impairment:** Elevated creatinine levels (2.3 mg/dL) suggest possible kidney dysfunction.\\n*   **Anemia:** Low hemoglobin levels (11.0 g/dL) indicate anemia.\\n*   **Pain Management:** The prescription of Oxycodone-Acetaminophen suggests the patient is experiencing pain.\\n*   **Potential Cardiac Issues:** Amiodarone and Metoprolol prescriptions may indicate underlying heart conditions such as arrhythmia or hypertension.\\n*   **Diabetes Mellitus:** GlipiZIDE, an antidiabetic medication, suggests the patient has type 2 diabetes.\\n\\n**3. Analysis of Prescriptions in Relation to Clinical Picture:**\\n\\n*   **Oxycodone-Acetaminophen:** Prescribed for pain relief. The shift from a higher dose (1-2 TAB or 5-10 ml) initially to a lower dose (1-2 TAB) may indicate improvement in pain management over the admission period.\\n*   **Amiodarone HCl:** Administered both intravenously and orally, likely for the management of cardiac arrhythmias.\\n*   **GlipiZIDE:** An oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes.\\n*   **Potassium Chloride:** Prescribed to supplement potassium levels, potentially due to diuretic use or other potassium-depleting conditions.\\n*   **Magnesium Sulfate:** Administered intravenously, possibly to address magnesium deficiency or for its antiarrhythmic properties.\\n*   **Metoprolol:** A beta-blocker, likely prescribed to manage heart rate and blood pressure, often used in the treatment of hypertension or certain arrhythmias.\\n*   **Fentanyl Patch:** A strong opioid analgesic, possibly prescribed for chronic pain management. It's initiation on 2190-07-20 suggests a need for longer-acting pain relief.\\n\\n**4. General Observations about Treatment Adequacy:**\\n\\n*   The prescriptions appear to address multiple health issues, including pain management, potential cardiac issues, diabetes, and electrolyte imbalances.\\n*   The use of both IV and oral medications suggests an initial acute phase requiring more immediate intervention, followed by a transition to oral medications for maintenance.\\n*   Monitoring of renal function is important considering the elevated creatinine levels and the use of medications that can potentially affect kidney function.\\n\\n**5. Points that Deserve Attention:**\\n\\n*   **Further Investigation of Renal Function:** The elevated creatinine level warrants further investigation to determine the underlying cause and severity of renal impairment.\\n*   **Anemia Evaluation:** The low hemoglobin level should be investigated to identify the cause of anemia and guide appropriate treatment.\\n*   **Age Information:** Obtaining the patient's age is crucial for a more accurate assessment and tailored treatment plan.\\n*   **Drug Interaction:** The concurrent use of multiple medications such as amiodarone and metoprolol should be carefully monitored due to the potential for drug interactions.\\n*   **Pain Management Strategy:** The transition to the Fentanyl patch requires careful monitoring for effectiveness and potential side effects, especially given the patient's age (when available) and renal function.\\n*   **Notes (24h Summary):** The absence of notes makes it difficult to get a clearer clinical picture. Detailed notes would give insights into the rationale behind the therapeutic decisions.\\n\",\n",
       " 'treatment_impact_assessment': \"Okay, I will analyze the treatment duration and potential patient impacts based on the provided patient data, the general health report, and the current Fentanyl patch prescription.\\n\\n**TREATMENT DURATION ANALYSIS:**\\n\\n*   **Estimated Treatment Duration:**\\n    *   The Fentanyl patch is prescribed from 2190-07-20 to 2190-07-25. Fentanyl patches are typically replaced every 72 hours, so this initial prescription covers approximately 5 days. The overall duration of Fentanyl patch therapy is difficult to estimate without knowing the underlying cause of pain and the patient's response to the medication. It could be short-term (weeks) or long-term (months or years) depending on the nature of the pain (acute vs. chronic).\\n    *   Other medications like Amiodarone, Metoprolol, and GlipiZIDE are likely long-term therapies for chronic conditions (arrhythmia/hypertension and diabetes).\\n\\n*   **Short-term vs. Long-term Therapy:**\\n    *   Fentanyl patch for pain: Could be either short-term for acute pain flares or long-term for chronic pain, requiring ongoing assessment.\\n    *   Amiodarone and Metoprolol: Likely long-term for cardiac management.\\n    *   GlipiZIDE: Long-term for diabetes management.\\n    *   Potassium Chloride: Short-term, potentially to address a temporary electrolyte imbalance.\\n    *   Magnesium Sulfate: Short-term, to address a deficiency or for antiarrhythmic effect.\\n\\n*   **Factors That May Extend or Shorten Treatment Period:**\\n    *   *Renal Impairment:*  The elevated creatinine (2.3 mg/dL) may prolong the duration of certain medications and necessitate lower doses or alternative medications, especially for pain management. Renal function needs close monitoring.\\n    *   *Pain Response:* The effectiveness of the Fentanyl patch will dictate how long it is needed. Inadequate pain control may necessitate dosage adjustments or a change in analgesic strategy.\\n    *   *Cardiac Stability:* Amiodarone and Metoprolol treatment duration will depend on the stability of the patient's cardiac condition.\\n    *   *Blood Glucose Control:* GlipiZIDE will be continued as long as it effectively manages blood sugar levels.\\n    *   *Anemia:* The presence of anemia (hemoglobin 11.0 g/dL) may complicate treatment and recovery. The underlying cause should be investigated.\\n\\n*   **Monitoring Frequency Requirements:**\\n    *   *Renal Function:* Creatinine levels should be monitored frequently (initially daily or every other day) to assess the impact of medications on kidney function.\\n    *   *Pain Levels:* Regular assessment of pain intensity and side effects of Fentanyl patch.\\n    *   *Cardiac Rhythm and Blood Pressure:* Continuous or frequent monitoring of heart rhythm and blood pressure, especially after Amiodarone and Metoprolol administration.\\n    *   *Blood Glucose:* Regular monitoring of blood glucose levels to assess GlipiZIDE effectiveness.\\n    *    *Respiratory Rate:* Monitor respiratory rate, particularly with the use of Fentanyl.\\n\\n**PATIENT IMPACT ASSESSMENT:**\\n\\n*   **Correlation with Patient's Medical History:**\\n    *   The patient's history indicates potential renal impairment, anemia, diabetes, and cardiac issues. These conditions will significantly influence the choice and duration of treatment.\\n\\n*   **Potential Side Effects Based on Patient Profile:**\\n    *   *Fentanyl Patch:*  Constipation, nausea, sedation, respiratory depression (especially concerning given potential age and renal impairment), confusion.\\n    *   *Amiodarone:*  Thyroid dysfunction, liver abnormalities, pulmonary toxicity, QT prolongation.\\n    *   *Metoprolol:*  Bradycardia, hypotension, fatigue, dizziness.\\n    *   *GlipiZIDE:*  Hypoglycemia.\\n    *   *All medications:*  Increased risk of side effects and drug interactions given the number of medications and potential renal impairment.\\n\\n*   **Quality of Life Considerations During Treatment:**\\n    *   *Pain Management:*  Effective pain control is crucial for maintaining quality of life. However, Fentanyl can cause significant side effects (sedation, constipation) that can negatively impact quality of life.\\n    *   *Cardiac Issues:*  Arrhythmias and hypertension can cause fatigue, shortness of breath, and chest pain, limiting physical activity.\\n    *   *Diabetes:*  Poorly controlled diabetes can lead to fatigue, frequent urination, and increased risk of infections.\\n    *   *Renal Impairment:* Can cause fatigue, swelling, and other systemic issues.\\n\\n*   **Impact on Existing Conditions or Comorbidities:**\\n    *   *Renal Impairment:* Many medications (including Fentanyl and Amiodarone) are cleared by the kidneys, so renal impairment can increase the risk of drug accumulation and side effects.\\n    *   *Cardiac Issues:* Amiodarone and Metoprolol can interact with other medications and exacerbate existing cardiac conditions.\\n    *   *Diabetes:* Opioids can affect blood sugar control.\\n\\n*   **Functional Limitations or Lifestyle Adjustments Needed:**\\n    *   *Driving:* Fentanyl patch can cause drowsiness and impair judgment, making driving unsafe.\\n    *   *Physical Activity:* Cardiac issues and pain can limit physical activity.\\n    *   *Diet:* Diabetes requires dietary modifications.\\n    *   *Hydration:* Renal impairment may require fluid restrictions or careful monitoring of fluid intake.\\n\\n**HISTORICAL CORRELATION:**\\n\\n*   **How Current Treatment Aligns with Past Medical History:**\\n    *   The current treatment aligns with the identified conditions: pain management (Fentanyl, Oxycodone), cardiac issues (Amiodarone, Metoprolol), diabetes (GlipiZIDE), and electrolyte imbalances (Potassium Chloride, Magnesium Sulfate).\\n\\n*   **Previous Treatment Responses or Complications:**\\n    *   Unknown, as there is no information on previous treatments.\\n\\n*   **Risk Factors Specific to This Patient:**\\n    *   *Renal Impairment:* Significantly increases the risk of drug-related complications.\\n    *   *Anemia:*  Need to determine the cause of the anemia and treat accordingly.\\n    *   *Polypharmacy:* Multiple medications increase the risk of drug interactions.\\n\\n*   **Contraindications Based on Medical Background:**\\n    *   Need to rule out any specific contraindications to Fentanyl patch based on the patient's detailed medical history (allergies, respiratory conditions, etc.).  Amiodarone has many drug interactions that need to be carefully considered.\\n\\n**IMPACT ANNOTATIONS:**\\n\\n*   **Physical Impacts:** Decreased energy levels (anemia, cardiac issues, renal impairment), reduced mobility (pain, cardiac issues), potential for constipation (Fentanyl).\\n*   **Emotional/Psychological Impacts:** Pain, chronic illness, and medication side effects can lead to anxiety, depression, and mood changes.\\n*   **Social/Family Life Implications:** Limitations in physical activity and potential cognitive impairment can affect social interactions and family responsibilities.\\n*   **Work/Professional Activity Considerations:** Depending on the severity of the conditions and the side effects of medications, the patient may need to take time off work or adjust their work duties.  Drowsiness or cognitive changes from Fentanyl might impair job performance.\\n*   **Financial Implications of Extended Treatment:** Medications, doctor visits, and potential hospitalizations can create a significant financial burden, especially with long-term conditions and Medicare coverage.\\n\\n**Important Notes:**\\n\\n*   The absence of the patient's age significantly limits the accuracy of this assessment.\\n*   The elevated creatinine and low hemoglobin require further investigation to determine the underlying causes.\\n*   Close monitoring of renal function and medication side effects is essential.\\n*   Detailed notes from the medical team are crucial for understanding the rationale behind treatment decisions and monitoring the patient's progress.\\n\",\n",
       " 'synthesized_health_report': {'treatment_duration_criticality': 'medium',\n",
       "  'patient_compliance_criticality': 'medium',\n",
       "  'lifestyle_impact_criticality': 'medium',\n",
       "  'monitoring_frequency_criticality': 'high',\n",
       "  'executive_summary': 'Patient 9 is a female with potential renal impairment, anemia, diabetes, and cardiac issues, currently prescribed Fentanyl for pain management alongside other medications like Amiodarone, Metoprolol, and GlipiZIDE. Treatment includes both short-term and long-term therapies addressing multiple health concerns. Key risks involve drug interactions, renal function decline, and Fentanyl side effects. Overall prognosis depends on managing pain effectively while minimizing side effects and addressing underlying conditions. Close monitoring is essential.',\n",
       "  'actionable_recommendations': '1. **Healthcare Provider Actions:**\\n    *   Investigate renal function and anemia to determine underlying causes.\\n    *   Closely monitor creatinine levels, potassium, hemoglobin, and blood glucose.\\n    *   Evaluate and manage potential drug interactions, particularly between Amiodarone and Metoprolol.\\n    *   Titrate Fentanyl patch dosage based on pain control and side effects, considering renal impairment.\\n    *   Monitor cardiac rhythm and blood pressure regularly.\\n2. **Patient Education and Compliance:**\\n    *   Educate the patient on potential Fentanyl side effects (constipation, sedation, respiratory depression) and provide strategies for managing them.\\n    *   Reinforce the importance of medication adherence for diabetes and cardiac conditions.\\n    *   Educate the patient on dietary modifications for diabetes and potential fluid restrictions for renal impairment.\\n3. **Follow-Up Scheduling and Care Coordination:**\\n    *   Schedule regular follow-up appointments to assess pain management, monitor side effects, and evaluate treatment effectiveness.\\n    *   Coordinate care between specialists (cardiologist, nephrologist, endocrinologist) to optimize treatment and manage comorbidities.\\n4. **Risk Mitigation Strategies:**\\n    *   Implement strategies to prevent falls and accidents due to potential dizziness or sedation from medications.\\n    *   Consider deprescribing medications if appropriate to reduce polypharmacy risks.\\n    *   Ensure patient has access to resources for managing chronic conditions, such as diabetes education and cardiac rehabilitation.'}}"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state_very_poisoned_sequential"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
